Why Americans Travel for Stem Cells: The FDA, Explained

Every year, thousands of Americans board flights for stem cell treatment abroad. The reason isn't only price — it's regulation. Understanding the FDA's actual position explains why certain therapies are widely available in Colombia but hard to get legally in the United States, and what that means for you as a patient.

How the FDA classifies stem cells

The FDA regulates human cells and tissues under a framework called HCT/Ps (21 CFR Part 1271). Where a therapy falls determines how heavily it's regulated:

• Section 361 — lightly regulated, no pre-approval needed — but only if the product meets all criteria, including "minimal manipulation" and "homologous use" (used for the same basic function as in the body it came from).
• Section 351 — treated as a biological drug requiring clinical trials and FDA approval — if the cells are more than minimally manipulated (e.g., culture-expanded) or used for an unrelated condition.

Here's the crux: culturing and expanding stem cells to high doses, or using donor cells to treat conditions far from their origin, generally pushes a therapy into the "drug" category — which means it needs approval that most clinics don't have.

What's actually FDA-approved

FDA-approved stem cell products are mostly limited to blood-forming (hematopoietic) cord-blood products for specific blood and immune disorders, plus a small number of advanced cell and gene therapies. In December 2025, for example, the FDA approved a gene-based stem cell therapy for Wiskott-Aldrich syndrome — backed by two clinical studies showing benefit. That high evidence bar is exactly the point: most MSC injections and exosome products are not FDA-approved for any condition, and remain investigational.

Enforcement is tightening

The FDA formally ended its enforcement-discretion grace period for these products and has stepped up action. Courts have backed the agency — including appellate rulings affirming that unproven stem cell therapies are subject to FDA regulation as drugs (cases involving US Stem Cell Clinic and Regenerative Sciences/Regenexx). In early 2026, the FDA issued warning letters to clinics in Florida, California, and Texas over unapproved exosome products. The direction of travel is more oversight, not less.

The state-law patchwork

Adding complexity, some states have passed laws that conflict with federal rules. Florida's 2025 law permits certain stem cell therapies for orthopedics, wound care, and pain management; Nevada and Utah have similar measures. These create gray zones — but federal authority still governs, and a state law doesn't make a product FDA-approved.

Why patients travel abroad

Inside the US, clinics that stay compliant are mostly limited to minimal-manipulation, same-day autologous procedures — things like bone-marrow concentrate (BMAC) or stromal vascular fraction (SVF) processed and re-injected during one visit. What's hard to get legally in the US is culture-expanded, high-count, donor (allogeneic) umbilical-cord cells.

Countries like Colombia regulate stem cell therapy through their own health authority (INVIMA) and permit GMP-lab-cultured allogeneic protocols that deliver far higher cell counts than a same-day US procedure. Combined with costs 50–70% lower, that's the core reason Americans travel: access to protocols and cell doses that simply aren't available at home, at a price they can afford.

'Legal abroad' isn't 'proven'

How to protect yourself

• Ask whether the treatment is supported by clinical-trial evidence for your specific condition — not just testimonials.
• Verify the clinic's regulatory standing and lab certification (INVIMA registration, GMP processing).
• Get cell source, count, and viability documentation in writing.
• Be skeptical of "cures," guaranteed results, or pressure to pay large deposits fast.
• Keep your home physician in the loop for follow-up and continuity.